Médicaments Dérivés du Plasma AO 2026-28

This tender, identified by TED notice 148999-2026, seeks the procurement of plasma-derived medicinal products for the period 2026-2028. The contracting authority, based in France, is issuing this open tender (AO) for supplies of these critical pharmaceuticals. The Common Procurement Vocabulary (CPV) code associated with this procurement is "Plasma extracts." This represents a significant opportunity for manufacturers and suppliers specializing in the production and distribution of a wide range of plasma-derived therapies.

Prospective bidders will likely be expected to demonstrate a robust track record in the pharmaceutical sector, with a particular focus on plasma fractionation and the manufacturing of sterile, high-quality medicinal products. Key requirements will typically include adherence to stringent regulatory standards, such as Good Manufacturing Practices (GMP), and the ability to ensure a consistent and reliable supply chain. Bidders may also need to provide detailed specifications of their product offerings, including proof of efficacy, safety profiles, and compliance with relevant European Medicines Agency (EMA) guidelines. Furthermore, experience in managing large-scale pharmaceutical contracts and providing comprehensive logistical support across France will be a crucial consideration for the contracting authority.

This procurement is vital for ensuring the continued availability of essential plasma-derived treatments within the French healthcare system.